StephenKWilliamsonMDRetired June 2021(he/him)

PubMed

• 9 citations
  Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA ...
  Anwaar Saeed, Robin Park, Harsh Pathak, Ayah Nedal Al-Bzour, Junqiang Dai
  Nature Communications. 2024-02-20
• Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
  Do-Youn Oh, Maria Alsina Maqueda, David I Quinn, Peter J O'Dwyer, Ian Chau
  BMC Cancer. 2023-11-03
• 5 citations
  A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarci...
  Weijing Sun, Nirmal Veeramachaneni, Raed Al-Rajabi, Rashna Madan, Anup Kasi
  Cancer Medicine. 2023-08-01

Journal Articles

• Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?  
  Chintala L, Vaka S, Baranda J, Williamson SK, Oncol Rev, 1/1/2011
• Chemotherapy in Head and Neck Cancer: Clinical Predictors of Tolerance and Outcomes  
  Kubicek GJ, Kimler BF, Wang F, Reddy EK, Girod DA, Williamson SK, Am J Clin Oncol, 1/24/2010
• Treatment of Gastric Cancer (Letter to editor)  
  Singh J, Williamson SK, Malani AK, NEJM, 1/1/2006
• N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC) Update on efficacy and quality of life ...  
  Williamson SK, Goldberg, RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Findlay BP, Cancer Conference Highlights, 1/1/2003
• A phase III study of carboplatin and paclitaxel with or without tirapazamine in patients with advanced NSCLC Southwest Oncology Group (SWOG) Trial Evaluates Addition o...  
  Williamson, SK, Current Clinical Trials in Thoracic Oncology, 1/1/2001
• Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength  
  Van Veldhuizen P, Taylor S, Williamson S, Drees B, J Urology, 1/1/2000
• Phase II evaluation of cisplatinum and etoposide followed by mitotane at progression in advanced and metastatic adenocortical carcinoma: A Southwest Oncology Group study  
  Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH, Crawford ED, Cancer, 1/1/2000
• Extragonadal germ cell tumors in brothers  
  D'Silva, SA, Williamson SK, Schimke RN, Am J Med Genetics, 1/1/1999
• Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group Phase II Trial  
  Hesketh PJ, Crowley JJ, Burris III HA, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore Jr. DF, Livingston RB, Gandara DR, The Cancer J from Scientific Am, 1/1/1999
• Phase II evaluation of Ifosfamide/Mesna in metastatic prostate cancer: A Southwest Oncology Group Study  
  Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED, Am. J. Clinical Oncology, 1/1/1996
• Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach: A Southwest Oncology Group Study  
  Williamson SK, Tangen CM, Maddox AM, Spiridonidis CH, Macdonald JS, Am. J. Clinical Oncology, 1/1/1995
• A pilot study of the physician acceptance of tele-oncology  
  Allen A, Hayes J, Sadasivan R, Williamson SK, and Wittman, J of Telemedicine and Telecare, 1/1/1995
• Phase II evaluation of Didemnin B in hormonally refractory metastatic prostate cancer: A Southwest Oncology Group Study  
  Williamson SK, Wolf MK, Eisenberger MA, O'Rourke MA, Brannon W, Crawford ED, Invest New Drugs, 1/1/1995
• The role of protracted 5-FU infusion plus radiotherapy in Rectal Cancer  
  Smalley SR, Williamson SK, J of Infusional Chemotherapy, 1/1/1994
• Radiotherapy alone in esophageal carcinoma: Current management and future directions of adjuvant, curative and palliative approaches  
  Smalley SR, Gunderson LL, Reddy EK, Williamson S, Sem Oncology, 1/1/1994
• Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer -- A Southwest Oncology Group Study  
  Grunberg, SM, Crowley, J, Livingston, R, Gill, I, Williamson, SK, O'Rourke, TO, Braun, T, Marshall, E, Weick, JK, Balcerzak, SP, and Martino, RL, J Clin Oncol, 1/1/1993
• Prolonged, alternating chemotherapy for extensive stage small cell lung cancer: A Southwest Oncology Group Study  
  Livingston, RB, Crowley, JJ, Thompson, T, Williamson, SK, Meyers, FJ, O'Rourke, TO, and Neefe, JR, Cancer, 1/1/1993
• Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer: A Southwest Oncology Group Study  
  Williamson, SK, Crowley, J, Livingston, RB, and Weiss, G, Invest New Drugs, 1/1/1993
• Pilot study of continuous infusion 5 fluorouracil, weekly adriamycin, and intermittent mitomycin C in advanced adenocarcinomas  
  Williamson SK, Taylor SA, Stephens RL, J of Infusional Chemotherapy, 1/1/1992
• Treatment of non small cell lung cancer with vinblastine and very high dose cisplatin A Southwest Oncology Group study  
  Grunberg, SM, Crowley, JJ, Livingston, RB, Muggia, FM, MacDonald, JS, Williamson SK, and Stephens, RL, Cancer Chemother. and Pharmacol, 1/1/1991
• Phase I evaluation of Spirogermanium and 5 fluorouracil in colorectal carcinoma  
  Williamson SK and Slavik M, Invest New Drugs, 1/1/1991
• Treatment of small cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study  
  Taylor, CW, Crowley, J, Williamson, SK, Miller, TP, Taylor, SA, Giri, PGS, Stephens, RL, and Livingston, RB, J Clin Oncol, 1/1/1990
• Clinical stage I testicular cancer: Orchiectomy without node dissection  
  Stephens RL, Williamson SK, Ann Int Med, 1/1/1988
• Aggressive weekly chemotherapy in small cell carcinoma of the lung  
  Williamson SK, Taylor SA, Am. J. Clinical Oncology, 1/1/1987
• Methotrexate cerebral spinal fluid pharmacokinetics in a lymphoma patient treated with m BACOD  
  Stephens RL, Williamson SK, Jackson WL, The American J. of Medicine, 1/1/1985
• Join now to see all

Books/Book Chapters

• Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach 
  Chapter: Radiation and combined modality therapy for cancer of the stomach 
  Page 9 - 36HJ WaneboLippincott-Raven Publishers1997

Abstracts/Posters

• A Phase I Trial of Irinotecan (Iri) and Buparlisib (B) in Previously Treated Patients (PTS) with Metastatic Colorectal Cancer (mCRC).
  J.C. Baranda, G. Reed, S. Williamson, M. Stoltz, R. Perez, C. Mackay, R. Madan, J.Scott, A, Meeting 2014 European Society for Medical Oncology, 2014 European Society for Medical Oncology, 1/26/2014
• Phase I clinical trial of the intraperitoneal (IP) administration of a novel nanoparticle formulation of paclitaxel (NTX).
  Williamson SK, Wick J, Chapman JA, Johnson G, Reed G, Schulz TK, Smith H, Weir S, Decedue CJ, Howell, J and Roby, K, Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 1/31/2013
• Docetaxel followed by temsirolimus suppresses mTOR pathway and can overcome PI3K / AKT over-activation mechanism of resistance in lung cancer cell line.
  Huang CH, Godachova A, Misra J, Holton E, Beaudoin C, Williamson, SK, Van Veldhuizen PJ, Annual Meeting of the American Association for Cancer Research, Washington, DC, 1/6/2013
• Phase I study of azacitidine and ciplatin in patients with advanced head and neck or non-small cell lung cancer.
  Liao Y-M, Mirshahidi H, Zhang K, Mirshahidi S, Williamson S, Hsueh C-T, Annual Meeting of the American Association for Cancer Research, Chicago, IL, 1/31/2012
• Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC).
  Govindarajan R, Siegel ER, Makhoul I, Williamson SK, Annual Gastrointestinal Cancer Symposium, San Francisco, CA, 1/15/2009
• Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC).
  Govindarajan R, Siegel ER, Makhoul I, Williamson SK, International Liver Cancer Association third annual conference, Milan, Italy, 1/4/2009
• SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung can...
  Le Q, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar L, Crowley JJ, Moore DF, Gandara DR, Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings Part I, 1/20/2008
• PDGFR inhibition using imatinib (I) combined with docetaxel (D), a potential new treatment strategy in the treatment of recurrent non-small cell lung cancer (NSCLC): P...
  Huang CH, Williamson S, VanVeldhuizen PJ, Hsueh CT, Allen A, Smith H, Mayo M, Tawfik O, Uypeckcuat AM, and Kelly K, Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings Part II, 1/20/2008
• A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
  Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/20/2007
• N9741: Survival update and prognostic factor analysis of oxaliplatin(Ox) and irinotecan(Iri) combinations for metastatic colorectal cancer (MCRC)
  Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/20/2007
• N9741: Survival update and prognostic factor analysis of oxaliplatin(Ox) and irinotecan(Iri) combinations for metastatic colorectal cancer(MCRC).
  Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part, 1/20/2007
• Phase II trial of imatinib and docetaxel in recurrent non-small cell lung cancer.
  Huang CH, Williamson S, VanVeldhuizen PJ, Hsueh CT, Smith H, Mayo M, Allen A, Kelly K, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/20/2007
• A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial.
  Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/20/2007
• Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials.
  Albain KS, Unger J,. Crowley JJ, Carolyn Gotay CC, Clark JI, Davies A, Edelman M, Herbst R, Kelly K, Williamson SK, Wozniak A, Gandara DR, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/1/2007
• Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenom...
  Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S, Williamson SK, Furuse K, McLeod HL, Mack PC, Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I, 1/1/2007
• Second Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacoge...
  Crowley JJ, Furuse K, Kawahara M, Fukushima M, Kawaguchi T, Williamson SK, Lara PN, Mack PC, Gandara DR, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, 1/20/2006
• A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial.
  Williamson SK, Moon J, Huang CH, Guaglianone P, Wolf GT, Urba SG, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, 1/20/2006
• Elevated Osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003.
  Mack PC, Redman MW, Chansky K, Williamson SK, Farneth N, Lara PN, Le Q, Gumerlock PH, Crowley JJ, Gandara DR, Proc ASCO 25, 42nd Annual Meeting of the American Society of Clinical Oncology, Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, Atlanta, GA, 1/20/2006
• A phase II trail of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial.
  Williamson S, Moon J, Hunag C, Wolf G, Urba S, European Journal of Cancer (supplement), 1/1/2005
• SWOG 0101: Evaluation of gemcitabine and irinotecan in esophageal cancer.
  Williamson SK, McCoy S, Abruzzeese JL, Program/Proceedings of the 2004 Gastrintestinal Cancers Symposium, San Francisco, CA, 1/22/2004
• N9741: oxaliplatin (oxal) + CPT-11 or 5-fluorouracil (5FU)/leucovorin (LV) in advanced colorectal cancer (CRC). Final efficacy data from an intergroup study.
  Goldberg, RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, Findlay B, Program/Proceedings of the 2004 Gastrintestinal Cancers Symposium, San Francisco, CA, 1/22/2004
• SWOG 0101: Evaluation of gemcitabine and irinotecan in esophageal cancer
  Williamson SK, McCoy S, Abruzzeese JL, Program/Proceedings of the 2004 Gastrintestinal Cancers Symposium, San Francisco, CA, 1/22/2004
• Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003.
  Galvin IV, Lara PN, Le Q, Chansky K, Crowley JJ, Williamson SK, Gandara DR, Gumerlock PH, Proc ASCO, 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 1/5/2004
• Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741.
  Fuchs C, Pollak M, Sargent DJ, Meyerhardt JA, Ramanathan RK, Williamson SK, Findlay B, Green E, Goldberg RM, Proc ASCO, 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 1/5/2004
• N9741: FOLFOX (oxaliplatin(Oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): Final efficacy d...
  Goldberg RM, Sargent DJ, Morton RF, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Pitot HR, Alberts SR, Proc ASCO, 40th Annual Meeting of the American Society of Clinical Oncology, 1/5/2004
• Join now to see all

Lectures

• Update on Hepatocelllular Carcinoma, an Oncologist's Perspective 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2011
• Update on AJCC Staging and use of EMR for staging 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2010
• Best of Oncology 2008 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2008
• Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenom... 
  1/1/2007
• Advances in Pancreatic, Gastric and Esophageal Cancers, Emerging Trends in Oncology, Including Updates from 2006 AACR and ASCO Meetings 
  Kansas City, MO - 1/24/2006
• Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications fo... 
  1/1/2006
• Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL,... 
  1/1/2006
• A phase II trail of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). A Southwest Oncology Group (SWOG) trial. 
  Paris, France - 1/30/2005
• Update on the Adjuvant Treatment of Colorectal Cancer 
  University of California – Davis, Sacramento, CA - 1/30/2004
• Update on investigational drug BAY 43-9006 and status of phase II trial in head and neck cancer. 
  Huntington Beach, CA - 1/29/2004
• Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). 
  New Orleans, LA - 1/5/2004
• Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group ... 
  New Orleans, LA - 1/5/2004
• Intergroup 0144 – phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous i... 
  Chicago, IL - 1/31/2003
• N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (... 
  Chicago, IL - 1/31/2003
• Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal ca... 
  Chicago, IL - 1/31/2003
• Paclitaxel/Carboplatin (PC) versus PC + Tirapazamine (PCT) in Advanced Non-Small Cell Lung Cancer (NSCLC). 
  Chicago, IL, 2003; Vancouver, Canada, 2003 - 1/10/2003
• Molecular Targeted Therapy of Cancer 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2003
• N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data fro... 
  Orlando, FL - 1/18/2002
• New Directions in the Treatment of Non Small Cell Lung Cancer 
  Coffeyville, KS - 1/7/2002
• Lung Cancer Treatment Update 
  Neosho Memorial Hospital, Chanute, KS, 2001; Pittsburg, KS, 2001 - 1/27/2001
• "Lung Cancer" 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2001
• Cytokine Gene Therapy for Malignant Melanoma. From Mice to Man to Mice 
  University of Kansas Medical Center, Kansas City, KS - 1/1/2001
• Cancer Care and Prevention: Gastro-Intestinal Cancer Awareness 
  Grandview, MO - 1/30/2000
• Non-Small-Cell Lung Cancer and the Southwest Oncology Group 
  UC Davis Cancer Center, Sacramento, CA - 1/24/2000
• Vaccine Therapy of Cancer 
  Kansas City, MO - 1/7/2000
• Join now to see all